Vertex Pharmaceuticals Inc VRTX
News
Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
Vertex to Participate in Upcoming Investor Conferences
Vertex Pharmaceuticals Raises Outlook Following Crinetics Acquisition
Vertex Reports Third Quarter 2026 Financial Results
Stock Futures Higher, Oil Lower as Investors Return to Risk
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
7 healthcare stocks that stand out as investors pay up for the sector
7 healthcare stocks that stand out as -2-
Vertex Appoints Daniel Brennan to its Board of Directors
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Vertex to Participate in Upcoming September Investor Conferences
Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint
Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs


